Inclusion Criteria: - Histologically or cytologically documented locally advanced or metastatic solid tumors for which standard therapies either do not exist or have proven ineffective or intolerable - Evaluable disease or disease measurable per Response Evaluation Criteria in Solid Tumors (RECIST) - Life expectancy >/= 12 weeks - Adequate hematologic and end organ function Exclusion Criteria: - History of prior significant toxicity from another MEK pathway inhibitor requiring discontinuation of treatment - History of prior significant toxicity from another PI3K or Akt pathway or mTOR inhibitor requiring discontinuation of treatment - Anti-cancer therapy within 28 days prior to first dose of study drug, except as stated in protocol - History of type I or type II diabetes mellitus requiring insulin - Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease) - Clinically significant history of liver disease, current alcohol abuse, or current known active infection with HIV, hepatitis B or hepatitis C virus - Active autoimmune disease - Pregnant or lactating women - Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms - History of glaucoma - History of retinal vein occlusion